Orbimed Advisors LLC Clovis Oncology, Inc. Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $7.52 Million - $29.4 Million	-1,913,234 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $11.8 Million - $23.6 Million	-919,066 Reduced 32.45%	1,913,234 $28.5 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $1.41 Million - $2.43 Million	80,100 Added 2.91%	2,832,300 $70.3 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $6.02 Million - $16.9 Million	517,630 Added 23.16%	2,752,200 $49.4 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $2.83 Million - $4.76 Million	-96,300 Reduced 4.13%	2,234,570 $65.6 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $18 Million - $24.3 Million	359,200 Added 18.22%	2,330,870 $123 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $24.1 Million - $35.3 Million	-417,000 Reduced 17.46%	1,971,670 $134 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $160 Million - $203 Million	2,388,670	2,388,670 $197 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.